CD1C and melanoma: In melanoma patients, the frequency of the CD1c+CD14+ cells increased, and for the DC vaccination strategy used in these patients, CD1c+CD14+ cells were omitted from the optimized protocol and might be even a potential target to improve immunotherapy [39,42].